Cargando…
Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early 2020 soon led to the global pandemic of Coronavirus Disease 2019 (COVID-19). Since then, the clinical and scientific communities have been closely collaborating to develop effective strategies for controlling the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226031/ https://www.ncbi.nlm.nih.gov/pubmed/34175366 http://dx.doi.org/10.1016/j.jconrel.2021.06.036 |
_version_ | 1783712197580423168 |
---|---|
author | Hasanzadeh, Akbar Alamdaran, Masoomeh Ahmadi, Sepideh Nourizadeh, Helena Bagherzadeh, Mohammad Aref Mofazzal Jahromi, Mirza Ali Simon, Perikles Karimi, Mahdi Hamblin, Michael R. |
author_facet | Hasanzadeh, Akbar Alamdaran, Masoomeh Ahmadi, Sepideh Nourizadeh, Helena Bagherzadeh, Mohammad Aref Mofazzal Jahromi, Mirza Ali Simon, Perikles Karimi, Mahdi Hamblin, Michael R. |
author_sort | Hasanzadeh, Akbar |
collection | PubMed |
description | The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early 2020 soon led to the global pandemic of Coronavirus Disease 2019 (COVID-19). Since then, the clinical and scientific communities have been closely collaborating to develop effective strategies for controlling the ongoing pandemic. The game-changing fields of recent years, nanotechnology and nanomedicine have the potential to not only design new approaches, but also to improve existing methods for the fight against COVID-19. Nanomaterials can be used in the development of highly efficient, reusable personal protective equipment, and antiviral nano-coatings in public settings could prevent the spread of SARS-CoV-2. Smart nanocarriers have accelerated the design of several therapeutic, prophylactic, or immune-mediated approaches against COVID-19. Some nanovaccines have even entered Phase IΙ/IIΙ clinical trials. Several rapid and cost-effective COVID-19 diagnostic techniques have also been devised based on nanobiosensors, lab-on-a-chip systems, or nanopore technology. Here, we provide an overview of the emerging role of nanotechnology in the prevention, diagnosis, and treatment of COVID-19. |
format | Online Article Text |
id | pubmed-8226031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82260312021-06-25 Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies Hasanzadeh, Akbar Alamdaran, Masoomeh Ahmadi, Sepideh Nourizadeh, Helena Bagherzadeh, Mohammad Aref Mofazzal Jahromi, Mirza Ali Simon, Perikles Karimi, Mahdi Hamblin, Michael R. J Control Release Review Article The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early 2020 soon led to the global pandemic of Coronavirus Disease 2019 (COVID-19). Since then, the clinical and scientific communities have been closely collaborating to develop effective strategies for controlling the ongoing pandemic. The game-changing fields of recent years, nanotechnology and nanomedicine have the potential to not only design new approaches, but also to improve existing methods for the fight against COVID-19. Nanomaterials can be used in the development of highly efficient, reusable personal protective equipment, and antiviral nano-coatings in public settings could prevent the spread of SARS-CoV-2. Smart nanocarriers have accelerated the design of several therapeutic, prophylactic, or immune-mediated approaches against COVID-19. Some nanovaccines have even entered Phase IΙ/IIΙ clinical trials. Several rapid and cost-effective COVID-19 diagnostic techniques have also been devised based on nanobiosensors, lab-on-a-chip systems, or nanopore technology. Here, we provide an overview of the emerging role of nanotechnology in the prevention, diagnosis, and treatment of COVID-19. Elsevier B.V. 2021-08-10 2021-06-25 /pmc/articles/PMC8226031/ /pubmed/34175366 http://dx.doi.org/10.1016/j.jconrel.2021.06.036 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Hasanzadeh, Akbar Alamdaran, Masoomeh Ahmadi, Sepideh Nourizadeh, Helena Bagherzadeh, Mohammad Aref Mofazzal Jahromi, Mirza Ali Simon, Perikles Karimi, Mahdi Hamblin, Michael R. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies |
title | Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies |
title_full | Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies |
title_fullStr | Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies |
title_full_unstemmed | Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies |
title_short | Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies |
title_sort | nanotechnology against covid-19: immunization, diagnostic and therapeutic studies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226031/ https://www.ncbi.nlm.nih.gov/pubmed/34175366 http://dx.doi.org/10.1016/j.jconrel.2021.06.036 |
work_keys_str_mv | AT hasanzadehakbar nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT alamdaranmasoomeh nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT ahmadisepideh nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT nourizadehhelena nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT bagherzadehmohammadaref nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT mofazzaljahromimirzaali nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT simonperikles nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT karimimahdi nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies AT hamblinmichaelr nanotechnologyagainstcovid19immunizationdiagnosticandtherapeuticstudies |